Compare GHI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
| Metric | GHI | ANIX |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 114.0M |
| IPO Year | 1998 | 2013 |
| Metric | GHI | ANIX |
|---|---|---|
| Price | $6.31 | $2.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.50 | $8.67 |
| AVG Volume (30 Days) | 58.8K | ★ 269.1K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | ★ 22.93% | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,389,766.00 | $210,000.00 |
| Revenue This Year | $273.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.71 | $2.32 |
| 52 Week High | $10.94 | $5.46 |
| Indicator | GHI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 31.69 |
| Support Level | $6.01 | $2.73 |
| Resistance Level | $6.76 | $3.09 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 25.68 | 2.51 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.